Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease

Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.

Inclusion Criteria:

• Diagnosis of AD
• Age 50-85
• MMSE 14-26
• Other Inclusion Criteria Apply

Exclusion Criteria:

• Significant Neurological Disease
• Major Psychiatric Disorder
• Clinically Significant Systemic Illness
• Other Exclusion Criteria Apply